- Home
- OGI vs IPSC Comparison
OGI vs IPSC Comparison
Compare OGI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- IPSC
- Stock Information
- Founded
- OGI 2013
- IPSC 2019
- Country
- OGI Canada
- IPSC United States
- Employees
- OGI N/A
- IPSC N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- OGI Health Care
- IPSC Health Care
- Exchange
- OGI Nasdaq
- IPSC Nasdaq
- Market Cap
- OGI 169.4M
- IPSC 149.1M
- IPO Year
- OGI N/A
- IPSC 2021
- Fundamental
- Price
- OGI $1.44
- IPSC $1.22
- Analyst Decision
- OGI
- IPSC Strong Buy
- Analyst Count
- OGI 0
- IPSC 4
- Target Price
- OGI N/A
- IPSC $13.00
- AVG Volume (30 Days)
- OGI 651.8K
- IPSC 462.0K
- Earning Date
- OGI 12-17-2024
- IPSC 11-05-2024
- Dividend Yield
- OGI N/A
- IPSC N/A
- EPS Growth
- OGI N/A
- IPSC N/A
- EPS
- OGI N/A
- IPSC N/A
- Revenue
- OGI $110,297,722.00
- IPSC $2,684,000.00
- Revenue This Year
- OGI $8.76
- IPSC $244.52
- Revenue Next Year
- OGI $14.04
- IPSC $27.73
- P/E Ratio
- OGI N/A
- IPSC N/A
- Revenue Growth
- OGI 2.33
- IPSC 7.88
- 52 Week Low
- OGI $1.19
- IPSC $1.14
- 52 Week High
- OGI $2.91
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- OGI 30.47
- IPSC 37.50
- Support Level
- OGI $1.52
- IPSC $1.14
- Resistance Level
- OGI $1.64
- IPSC $1.50
- Average True Range (ATR)
- OGI 0.10
- IPSC 0.14
- MACD
- OGI -0.03
- IPSC -0.00
- Stochastic Oscillator
- OGI 0.00
- IPSC 18.65
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.